What’s Going On With Signet Jewelers Stock Today?

Signet Jewelers Ltd (NYSE:SIG) and Leonard Green & Partners, L.P. announce a significant strategic move, amending Series A Convertible Preference Shares to net share settlement and repurchasing half of the Preferred Shares. CEO Virginia C. Drosos emphasizes the company's robust performance, marked by double-digit revenue growth, enhanced gross margins, and a substantial increase in non-GAAP diluted earnings per share, along with significant returns to shareholders.

Signet Jewelers Ltd (NYSE:SIG) shares are trading higher today in the premarket session.

The company and Leonard Green & Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares.

“LGP has been a strong supporter of Signet through our transformation journey from the time of our agreement in 2016 and throughout the execution of our Path to Brilliance strategy. Since launching this strategy, Signet has grown revenue double digits while optimizing our fleet, increased gross margins by more than 400 basis points, drove a nearly 60% increase to our non-GAAP diluted earnings per share, and returned more than $1.5 billion to shareholders while investing for future competitive advantage,” said Virginia C. Drosos, Signet’s Chief Executive Officer.

The referred shares, scheduled to mature in November 2024, were convertible into approximately 8.2 million Signet common shares.

Signet will repurchase half of the Preferred Shares for approximately $414 million in cash,and after the transaction there will be $328 million remaining in stated value of the preferred shares which carry a dividend of 5.0%.

The transaction will immediately reduce Signet’s diluted share count by approximately 4.1 million shares, or 7.6% of Signet’s diluted share count. 

Signet will settle the transaction from the $1.4 billion in cash on hand at the end of Fiscal 2024. 

As a result of the above, Signet increased its FY25 adjusted EPS outlook to $9.90 – $11.52 from $9.08 – $10.48 versus an estimate of $9.72.

This revised range reflects the diluted share impact of the repurchase and amendment with a weighted average diluted share count of approximately 46.3 million shares for Fiscal 2025 and excludes the deemed dividend to net income available to common shareholders of $83 million.

Price Action: SIG shares are trading higher by 3.28% at $98.19 in premarket on the last check Wednesday.

Photo via Shutterstock

Total
0
Shares
Related Posts
Read More

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

BCAB

Read More

Canadian Giant SNDL Speeds Up Acquisition Of Majority Positions In Two US Cannabis Companies As Marijuana Rescheduling Looms

SNDL Inc. through its joint venture with SunStream Bancorp Inc., announced on Thursday that SunStream USA group of companies will proceed with the process of acquisition of equity positions in U.S. cannabis assets, following the completion of a review by SNDL's listing authority, NASDAQ. SunStream USA I, LLC and SunStream USA II, LLC are among the entities that comprise the SunStream USA Group, with each entity including one or more third-party investors, all independently managed and governed.The Calgary, Alberta-based company said on Thursday that SNDL's affiliate, SunStream Opportunities II LP, is anticipated to own non-voting and non-participating exchangeable securities in the SunStream USA entities.  

SNDL

Read More

What’s Going On With Pfizer On Thursday? Pharma Giant’s Shares Tick Lower

Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys aged 4 to 7 using a modified human dystrophin gene, the trial showed no significant progress, affecting Pfizer's quest for new treatments as it diversifies beyond its COVID-19 portfolio.

PFE